A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

by Niels D. Prins, John E. Harrison, Hui-May Chu, Kelly Blackburn, John J. Alam, Philip Scheltens, for the REVERSE-SD Study Investigators
Published 2021-05-01